Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22039422 | 1.00 | MEN1 (0.48) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL2707261 | 0.95 | MEN1 (0.43) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL31444392 | 0.95 | MEN1 (0.43) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL22097356 | 0.87 | MEN1 (0.44) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL4102503 | 0.87 | MEN1 (0.44) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL3333995 | 0.83 | MEN1 (0.46) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL167408 | 0.83 | MEN1 (0.50) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL6180379 | 0.83 | MEN1 (0.50) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL28840102 | 0.83 | MEN1 (0.46) | MEN1KMT2AKCNH2CHRM2CHRM4 | |
| SCHEMBL31444359 | 0.83 | MEN1 (0.50) | MEN1KMT2AKCNH2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |